MAPK3 and cancer: In this study, the MEK1/2-ERK1/2 cascade was rapidly hyperactivated within hours by TBMS1 treatment, leading to a toxic stress to cancer cells, indicating that TBMS1 could be a promising anti-cancer drug that is different from traditional strategy.